Endothelin in heart failure

Current Hypertension Reports

Volumn 1, Issue 1, 1999, Pages 62-68

  Sütsch, Gabor ^a   Barton, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ANIMAL; CONGESTIVE HEART FAILURE; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR RESISTANCE;

ANIMALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ENDOTHELIN; VASCULAR RESISTANCE;

EID: 0033068873     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0075-9     Document Type: Article

References (81)

1. Sagmeister M, Gessner U, Oggier W, et al.: An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997, 18:1102-1109.
2. American Heart Association. Heart and Stroke Facts. (Statistical supplement). Dallas: American Heart Association; 1996.
3. Graves EJ: National Center for Health Statistics. 1993 Summary: National Hospital Discharge Survey. Hyattsville, MD: Vital Health Statistics 1995, 13(121):1-63.
4. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994, 13(suppl):107-112.
5. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435. (Pubitemid 17079089)
6. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293 302.
7. The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992, 327:669-677.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828. (Pubitemid 23285909)
9. Rickenbacher PR, Trindade PT, Haywood GA, et al.: Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol 1996, 27:1192-1197.
10. Kiowski W, Sütsch G, Dössegger L: Clinical benefit of angiotensin- converting enzyme inhibitors in chronic heart failure. J Cardiovasc Pharmacol 1996, 27:S19-S24. (Pubitemid 26134258)
11. Shan K, Kurrelmeyer K, Seta Y, et al.: The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997, 12:218-223. (Pubitemid 27252528)
12. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415. (Pubitemid 18090241)
13. Wagner OF, Christ G, Wojta J, et al.: Polar secretion of endothelin- 1 by cultured endothelial cells. J Biol Chem 1992, 267:16066-16068.
14. Levin ER: Endothelins. N Engl J Med 1995, 333:356-363.
15. Levin ER: Endothelins as cardiovascular peptides. Am J Nephrol 1996, 16:246-251.
16. Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998, 16:1081-1098.
17. Kashiwabara T, Inagaki Y, Ohta H, et al.: Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. Febs Lett 1989, 247:73-76. (Pubitemid 19092293)
18. Hirata Y, Kanno K, Watanabe TX, et al.: Receptor binding and vasoconstrictor activity of big endothelin. Eur J Pharmacol 1990, 176:225-228. (Pubitemid 20041295)
19. Plumpton C, Haynes WG, Webb DJ, Davenport AP: Phosphoramidon inhibition of the in vivo conversion of big endothelin- 1 to endothelin-1 in the human forearm. Br J Pharmacol 1995, 116:1821 1828.
20. Riezebos J, Watts IS, Vallance PJ: Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol 1994, 111:609-615. (Pubitemid 24146121)
21. Takayanagi R, Kitazumi K, Takasaki C, et al.: Presence of nonselective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. Febs Lett 1991, 282:103- 106.
22. Hirata Y, Emori T, Eguchi S, et al.: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993, 91:1367-1373. (Pubitemid 23127334)
23. Haynes WG, Strachan FE, Webb DJ: Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995, 92:357-363.
24. Gray GA, Löffler BM, Clozel M: Characterization of endothelin receptors mediating contraction of rabbit saphenous vein. Am J Physiol 1994, 266:H959-H966.
25. Seo B, Oemar BS, Siebenmann R, et al.: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89:1203-1208.
26. Docherty CC, MacLean MR: EndothelinB receptors in rabbi pulmonary resistance arteries: effect of left ventricular dysfunction. J Pharmacol Exp Ther 1998, 284:895-903. (Pubitemid 28130815)
27. Anggard E, Galton S, Rae G, et al.: The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 1989, 13:46-49.
28. Fukuroda T, Fujikawa T, Ozaki S, et al.: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199:1461-1465.
29. Pierre LN, Davenport AP: Relative contribution of endothelin A and endothelin B receptors to vasoconstriction in small arteries from human heart and brain. J Cardiovasc Pharmacol 1998, 31:74-76.
30. Yang Z, Richard V, Von Segesser L, et al.: Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? Circulation 1990, 82:188-195.
31. Kiowski W, Lüscher TF, Linder L, Bühler FR: Endothelin-1- induced vasoconstriction in humans: reversal by calciu channel blockade but not by nitrovasodilators or endothelium- derived relaxing factor. Circulation 83:469-475.
32. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994, 344:852-854. (Pubitemid 24290383)
33. Haynes WG, Moffat S, Webb DJ. An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Clin Pharmacol 1995, 40:307-311.
34. Haynes WG, Ferro CJ, O'Kane KPJ, et al.: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860- 1870. (Pubitemid 26154037)
35. Sütsch G, Fleisch M, Yan XW, et al.: Acute hemodynamic and renal effects of the endothelin-1 receptor antagonist TAK-044 in patients without heart failure. J Am Coll Cardiol 1997, 29(suppl): 444.
36. Dupuis J, Stewart DJ, Cernacek P, Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94:1578-1584. (Pubitemid 26320261)
37. Tsutamoto T, Wada A, Maeda Y, et al.: Relation between endothelin- 1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23:1427-1433. (Pubitemid 24158013)
38. Cannan CR, Burnett JC, Lerman A: Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996, 93:646-651. (Pubitemid 26052447)
39. Dagassan PH, Breu V, Clozel M, et al.: Up-regulation of endothelin- B receptors in atherosclerotic human coronary arteries J Cardiovasc Pharmacol 1996, 27:147-153.
40. Zeiher AM, Goebel H, Schächinger V, Ihling C: Tissue endothelin- 1 immunoreactivity in the active coronary atherosclerotic plaque. Circulation 1995, 91:941-947.
41. Ito H, Hiroe M, Hirata Y, et al.: Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994, 89:2198-2203.
42. Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995, 96:1059-1065.
43. Komuro I, Kurihara H, Sugiyama T, et al.: Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. Febs Lett 1988, 238:249-252.
44. Kita S, Taguchi Y, Matsumura Y: Endothelin-1 enhances pressor responses to norepinephrine: involvement of endothelin- B receptor. J Cardiovasc Pharmacol 1998, 31(Suppl):119-121.
45. Hirata Y, Kanno K, Eguchi S, Kano H: Effect of an AT1 receptor antagonist (CV-11974) on angiotensin II-induced cardiomyocyte hypertrophy in vitro. Blood Press 1994, 5(Suppl):84-88. (Pubitemid 24380446)
46. Moreau P, d'Uscio LV, Shaw S, et al.: Angiotensin II increases tissue endothelin and induces vascular hypertrophy in vivo: reversal by ETA-receptor antagonist. Circulation 1997, 96:1593-1597.
47. Kaddoura S, Firth JD, Boheler KR, et al.: Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation 1996, 93:2068-2079.
48. Moravec CS, Reynolds EE, Stewart RW, Bond M: Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun 1989, 159:14-18. (Pubitemid 19087606)
49. Thomas PB, Liu EC, Webb ML, et al.: Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol 1996, 271:2629-2637.
50. Clozel M, Clozel JP: Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther 1989, 250:1125-1131. (Pubitemid 19246730)
51. Clozel JP, Clozel M: Effects of endothelin on the coronary vascular bed in open-chest dogs. Circ Res 1989, 65:1193-1200. (Pubitemid 19281704)
52. Sorensen SS, Madsen JK, Pedersen EB: Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 1994, 266:411-418.
53. Vierhapper H, Wagner O, Nowothny P, Waldhäusl W: Effect of endothelin-1 in man. Circulation 1990, 81:1415-1418. (Pubitemid 20119641)
54. Kiely DG, Cargill RI, Struthers AD, Lipworth BJ: Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997, 33:378-386. (Pubitemid 27072643)
55. McMurray JJ, Ray SG, Abdullah I, et al.: Plasma endothelin in chronic heart failure. Circulation 1992, 85:1374-1379.
56. Wei CM, Lerman A, Rodeheffer RJ, et al.: Endothelin in human congestive heart failure. Circulation 1994, 89:1580-1586. (Pubitemid 24114234)
57. Love MP, McMurray JJ: Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 1996, 31:665-674. (Pubitemid 26175131)
58. Cody RJ, Haas GJ, Binkley PF, et al.: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85:504-509.
59. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JJ: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992, 67:719-724.
60. Kiowski W, Sütsch G, Hunziker P, et al.: Evidence for endothelin- 1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732-736.
61. Sütsch G, Bertel O, Kiowski W: Acute and short-term effects o the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997, 10:717-725. (Pubitemid 27129775)
62. Sütsch G, Kiowski W, Yan XW, et al.: Short-term oral endothelin- receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262 2268.
63. Galatius-Jensen S, Wroblewski H, Emmeluth C, et al.: Plasma endothelin in congestive heart failure: a predictor of cardiac death? J Cardiac Fail 1996, 2:71-76.
64. Pousset F, Isnard R, Lechat P, et al.: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997, 18:254 258.
65. Pacher R, Stanek B, Hulsmann M, et al.: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996, 27:633-641. (Pubitemid 26081922)
66. Omland T, Lie RT, Aakvaag A, et al.: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994, 89:1573-1579. (Pubitemid 24114233)
67. Krum H, Goldsmith R, Wilshire CM, et al.: Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995, 75:1282-1283.
68. Love MP, Haynes WG, Gray GA, et al.: Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996, 94:2131-2137.
69. Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of mycardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353-355. This is the first report that shows a benefit from prolonged endothelin- receptor blockade in an experimental CHF model.
70. Mulder P, Richard V, Derumeaux G, et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation 1997, 96:1976- 1982. (Pubitemid 27400761)
71. Pönicke K, Vogelsang M, Heinroth M, et al.: Endothelin receptors in the failing and nonfailing human heart. Circulation 1998, 97:744-751. (Pubitemid 28135336)
72. Barton M, Shaw S, d'Uscio LV, et al.: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA-receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861-865.
73. Barton M, d'Uscio L, Shaw S, et al.: ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31:499-504.
74. Barton M, Haudenschild CC, d'Uscio LV, et al.: Endothelin ETA receptor blockade restores nitric oxide-mediated endothelial function and inhibits atherosclerosis in apoE-deficient mice Proc Natl Acad Sci U S A 1998, 95:14367-14372.
75. Katz SD: Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 1997, 12:259-264. (Pubitemid 27252533)
76. Kiowski W, Sütsch G, Schalcher C, et al.: Endothelial control of vascular tone in chronic heart failure J Cardiovasc Pharmacol 1998, 32:(Suppl 3), in press.
77. Krum H, Katz SD: Effect of endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with hear failure. Am J Cardiol 1998, 81:355-358. (Pubitemid 28099317)
78. Ikeda U, Yamamoto K, Maeda Y, et al.: Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997, 29:65-69. (Pubitemid 27078343)
79. Prie S, Stewart DJ, Dupuis J: Endothelin A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline- induced pulmonary hypertension. Circulation 1998, 97:2169-2174. (Pubitemid 28262125)
80. Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990, 85:587-590. (Pubitemid 20070070)
81. Barton M, d'Uscio LV, Shaw S, et al.: Dysfunctional renal nitric oxide synthase and increased endothelin-1 in Dahl salt-sensitive hypertension: modulation by chronic ETA receptor blockade. Hypertension 1998, 32:632.